Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA)

被引:16
作者
Wang, LC [1 ]
Huhle, G [1 ]
Malsch, R [1 ]
Hoffmann, U [1 ]
Song, XH [1 ]
Harenberg, J [1 ]
机构
[1] Univ Heidelberg, Dept Med, Fac Clin Med Mannheim, D-68167 Mannheim, Germany
关键词
antibody; fluorescence linked immunofiltration assay; relative fluorescence intensity; heparin-induced thrombocytopenia;
D O I
10.1016/S0022-1759(98)00186-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A fluorescence-linked immunofiltration assay (FLIFA) was developed for the determination of heparin-induced IgG in heparin-induced thrombocytopenia (HIT) type II patients. Protein A was immobilized on a nitrocellulose membrane to bind heparin-induced IgG of HIT type II patients. Fluorescein-5-isothiocynate (FITC)-heparin was added to platelet factor 4 present in normal serum to form the neo-antigen which was captured by heparin-induced IgG. The heparin-induced IgG was quantified by the relative fluorescence intensity (RFI) of bound FITC-heparin. Values were expressed as a RFI ratio (RFI patient / RFI normal) and were 1.965 +/- 0.313 in HIT type II patients (n = 36) and 1.063 +/- 0.162 in healthy controls (n = 50, p < 0.0001). The intra- and inter-assay coefficients of variation were 4.9 and 10.4%, respectively. The heparin-induced IgG FLIFA will be useful in individual and epidemiological studies in patients during treatment with heparin. The FLIFA technique offers an alternative, rapid and sensitive methodological approach for studies on the interaction between antigen-antibody or ligand-receptor. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 22 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]   Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia [J].
Amiral, J ;
MarfaingKoka, A ;
Wolf, M ;
Alessi, MC ;
Tardy, B ;
BoyerNeumann, C ;
Vissac, AM ;
Fressinaud, E ;
Poncz, M ;
Meyer, D .
BLOOD, 1996, 88 (02) :410-416
[3]   Fc gamma RIIA H/R(131) polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis [J].
Arepally, G ;
McKenzie, SE ;
Jiang, XM ;
Poncz, M ;
Cines, DB .
BLOOD, 1997, 89 (02) :370-375
[4]   HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS [J].
ASTER, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1374-1376
[5]  
GREEN D, 1978, J LAB CLIN MED, V91, P167
[6]  
GREINACHER A, 1991, THROMB HAEMOSTASIS, V66, P734
[7]   CHARACTERIZATION OF HEPARINS BY HIGH-PERFORMANCE SIZE EXCLUSION LIQUID-CHROMATOGRAPHY [J].
HARENBERG, J ;
DEVRIES, JX .
JOURNAL OF CHROMATOGRAPHY, 1983, 261 (02) :287-292
[8]   Anticoagulation in patients with heparin-induced thrombocytopenia type II [J].
Harenberg, J ;
Huhle, G ;
Piazolo, L ;
Wang, LCU ;
Heene, DL .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (02) :189-196
[9]  
HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7
[10]  
Kelton JG, 1995, AM J CLIN PATHOL, V104, P611